← Back to Search

Ferumoxytol + Vitamin C for Glioblastoma (XACT-Fe-GBM-01 Trial)

Phase 1
Recruiting
Research Sponsored by Bryan Allen
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Aged 18 years or older
Not have significant co-morbid central nervous system disease, such as multiple sclerosis
Must not have
Prior radiation treatment that would result in field overlap
G6PD deficiency
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 36 months post-radiation
Awards & highlights

Summary

This trial tests adding ferumoxytol & vitamin C to standard brain tumor treatment to see if it helps adults.

Who is the study for?
Adults over 18 with newly diagnosed glioblastoma or diffuse midline glioma, able to start treatment within 6 weeks of surgery and take oral medication. Participants must be medically fit for standard therapy, not pregnant or breastfeeding, without significant other CNS diseases or conditions like hemochromatosis, G6PD deficiency, uncontrolled illnesses, certain drug dependencies (e.g., warfarin), and no prior overlapping radiation treatments.
What is being tested?
The trial is testing the addition of ferumoxytol (an iron supplement) and high-dose vitamin C to the usual chemoradiation treatment for brain tumors. All participants will receive these additional treatments alongside standard care with temozolomide chemotherapy and external beam radiation therapy.
What are the potential side effects?
Potential side effects include allergic reactions to ferumoxytol, increased risk of infection due to immune system suppression from chemotherapy, fatigue from radiation therapy, digestive issues from both chemo and high-dose vitamin C intake. Side effects can vary based on individual health conditions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
I do not have a major brain condition like multiple sclerosis.
Select...
I can care for myself and am up more than 50% of my waking hours.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have had radiation treatment in the same area before.
Select...
I have G6PD deficiency.
Select...
I need iron supplements for my health.
Select...
My kidney function tests are within the required range.
Select...
I require insulin for my diabetes.
Select...
I am currently taking HIV medication.
Select...
I have a history of hemochromatosis.
Select...
I am currently taking warfarin, flecainide, methadone, amphetamines, quinidine, or chlorpropamide and cannot change my medication.
Select...
I do not have any uncontrolled illnesses.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 36 months post-radiation
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 36 months post-radiation for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Determination of recommended phase 2 ferumoxytol dosing regimen
Secondary study objectives
Clinical response
Estimate Objective Response Rate (ORR)
Estimate overall survival (OS)
+3 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: Cohort 2Experimental Treatment4 Interventions
Radiation Phase * Ascorbate: 87.5 g administered intravenously (IV) three times each calendar week for approximately 8 weeks. * Ferumoxytol: 512 g administered intravenously (IV) the day before radiation, about 1 week after dose 1, during weeks 5 to 6 of radiation therapy, and then a week after that (for a total of 4 ferumoxytol infusions). * Radiation: 61.2 Gray (given 1.8 Gray once daily, 5 days per week, for about 7 weeks) or 60 Gray (2.0 Gray once daily for 5 days per week for about 6 weeks) * Temozolomide: 75 mg/m2, taken orally, once daily, every day, for up to 49 days or until radiation is completed (whichever comes first). Adjuvant Phase * Temozolomide: 150 to 200 mg/m2, taken orally, once daily, for five days out of 28 days (where 28 days is one cycle of chemotherapy) for up to six cycles * Ascorbate: 87.5 g administered intravenously (IV) twice each calendar week of the cycle * Ferumoxytol: 512 g administered intravenously (IV) the first day of the first cycle of
Group II: Cohort 1 (starting)Experimental Treatment4 Interventions
Radiation Phase * Ascorbate: 87.5 g administered intravenously (IV) three times each calendar week for approximately 8 weeks. * Ferumoxytol: 512 g administered intravenously (IV) the day before radiation and then during weeks 5 to 6 of radiation therapy. * Radiation: 61.2 Gray (given 1.8 Gray once daily, 5 days per week, for about 7 weeks) or 60 Gray (2.0 Gray once daily for 5 days per week for about 6 weeks) * Temozolomide: 75 mg/m2, taken orally, once daily, every day, for up to 49 days or until radiation is completed (whichever comes first). Adjuvant Phase * Temozolomide: 150 to 200 mg/m2, taken orally, once daily, for five days out of 28 days (where 28 days is one cycle of chemotherapy) for up to six cycles * Ascorbate: 87.5 g administered intravenously (IV) twice each calendar week of the cycle * Ferumoxytol: 512 g administered intravenously (IV) the first day of the first cycle of chemotherapy.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
External beam radiation therapy
2009
Completed Phase 3
~520
Temozolomide
2010
Completed Phase 3
~1880

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH
13,842 Previous Clinical Trials
41,002,988 Total Patients Enrolled
326 Trials studying Glioblastoma
23,170 Patients Enrolled for Glioblastoma
Bryan AllenLead Sponsor
3 Previous Clinical Trials
119 Total Patients Enrolled
1 Trials studying Glioblastoma
90 Patients Enrolled for Glioblastoma
Holden Comprehensive Cancer CenterOTHER
26 Previous Clinical Trials
755 Total Patients Enrolled
2 Trials studying Glioblastoma
90 Patients Enrolled for Glioblastoma

Media Library

External Beam Radiation Therapy Clinical Trial Eligibility Overview. Trial Name: NCT04900792 — Phase 1
Glioblastoma Research Study Groups: Cohort 1 (starting), Cohort 2
Glioblastoma Clinical Trial 2023: External Beam Radiation Therapy Highlights & Side Effects. Trial Name: NCT04900792 — Phase 1
External Beam Radiation Therapy 2023 Treatment Timeline for Medical Study. Trial Name: NCT04900792 — Phase 1
~4 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top